HRP970493A2 - Oral delayed immediate release medical formulation and method for preparing the same - Google Patents

Oral delayed immediate release medical formulation and method for preparing the same Download PDF

Info

Publication number: HRP970493A2
Authority: HR; Croatia
Prior art keywords: immediate release; formulation; oral administration; coating; core
Prior art date: 1996-09-23

Application number

HR96202651,4A

Other languages

English (en)

Croatian (hr)

Inventor

Wienman E Phlips

Original Assignee

Wienman E. Phlips

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-09-23

Filing date

1997-09-16

Publication date

1998-08-31

1997-09-16 Application filed by Wienman E. Phlips filed Critical Wienman E. Phlips

1998-08-31 Publication of HRP970493A2 publication Critical patent/HRP970493A2/hr

Links

239000000203 mixture Substances 0.000 title claims abstract description 139
238000009472 formulation Methods 0.000 title claims abstract description 90
239000012729 immediate-release (IR) formulation Substances 0.000 title claims abstract description 76
230000003111 delayed effect Effects 0.000 title claims abstract description 48
238000000034 method Methods 0.000 title claims abstract description 21
239000011248 coating agent Substances 0.000 claims abstract description 89
238000000576 coating method Methods 0.000 claims abstract description 89
239000013543 active substance Substances 0.000 claims abstract description 45
150000001875 compounds Chemical class 0.000 claims abstract description 20
230000002496 gastric effect Effects 0.000 claims abstract description 14
239000012530 fluid Substances 0.000 claims abstract description 12
239000000969 carrier Substances 0.000 claims abstract description 9
108090000623 proteins and genes Proteins 0.000 claims abstract description 7
102000004169 proteins and genes Human genes 0.000 claims abstract description 7
229960005486 vaccine Drugs 0.000 claims abstract description 6
230000001088 anti-asthma Effects 0.000 claims abstract description 4
239000000924 antiasthmatic agent Substances 0.000 claims abstract description 4
108090000790 Enzymes Proteins 0.000 claims abstract description 3
102000004190 Enzymes Human genes 0.000 claims abstract description 3
108091034117 Oligonucleotide Proteins 0.000 claims abstract description 3
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims abstract description 3
230000003474 anti-emetic effect Effects 0.000 claims abstract description 3
230000003356 anti-rheumatic effect Effects 0.000 claims abstract description 3
230000000767 anti-ulcer Effects 0.000 claims abstract description 3
239000000935 antidepressant agent Chemical class 0.000 claims abstract description 3
229940005513 antidepressants Drugs 0.000 claims abstract description 3
239000002111 antiemetic agent Substances 0.000 claims abstract description 3
229940125683 antiemetic agent Drugs 0.000 claims abstract description 3
239000002220 antihypertensive agent Chemical class 0.000 claims abstract description 3
229940030600 antihypertensive agent Drugs 0.000 claims abstract description 3
239000003435 antirheumatic agent Substances 0.000 claims abstract description 3
239000002249 anxiolytic agent Chemical class 0.000 claims abstract description 3
239000000496 cardiotonic agent Substances 0.000 claims abstract description 3
230000003177 cardiotonic effect Effects 0.000 claims abstract description 3
239000003246 corticosteroid Substances 0.000 claims abstract description 3
229960001334 corticosteroids Drugs 0.000 claims abstract description 3
102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 3
108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 3
239000000932 sedative agent Chemical class 0.000 claims abstract description 3
229940125723 sedative agent Drugs 0.000 claims abstract description 3
230000003110 anti-inflammatory effect Effects 0.000 claims abstract 4
230000002456 anti-arthritic effect Effects 0.000 claims abstract 2
239000003795 chemical substances by application Substances 0.000 claims description 23
239000000463 material Substances 0.000 claims description 22
239000004014 plasticizer Substances 0.000 claims description 13
229940079593 drug Drugs 0.000 claims description 10
239000003814 drug Substances 0.000 claims description 10
239000000454 talc Substances 0.000 claims description 9
229910052623 talc Inorganic materials 0.000 claims description 9
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 6
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 6
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 5
URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 claims description 5
239000001856 Ethyl cellulose Substances 0.000 claims description 4
ZFOZVQLOBQUTQQ-UHFFFAOYSA-N Tributyl citrate Chemical compound CCCCOC(=O)CC(O)(C(=O)OCCCC)CC(=O)OCCCC ZFOZVQLOBQUTQQ-UHFFFAOYSA-N 0.000 claims description 4
DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 claims description 4
239000002775 capsule Substances 0.000 claims description 4
235000019325 ethyl cellulose Nutrition 0.000 claims description 4
229920001249 ethyl cellulose Polymers 0.000 claims description 4
239000001069 triethyl citrate Substances 0.000 claims description 4
VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 claims description 4
235000013769 triethyl citrate Nutrition 0.000 claims description 4
229960003971 influenza vaccine Drugs 0.000 claims description 3
235000019359 magnesium stearate Nutrition 0.000 claims description 3
229960002622 triacetin Drugs 0.000 claims description 3
229910002012 Aerosil® Inorganic materials 0.000 claims description 2
208000027530 Meniere disease Diseases 0.000 claims description 2
239000002202 Polyethylene glycol Substances 0.000 claims description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 2
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 2
229940035676 analgesics Drugs 0.000 claims description 2
239000000730 antalgic agent Substances 0.000 claims description 2
230000000949 anxiolytic effect Effects 0.000 claims description 2
239000001087 glyceryl triacetate Substances 0.000 claims description 2
235000013773 glyceryl triacetate Nutrition 0.000 claims description 2
229920001223 polyethylene glycol Polymers 0.000 claims description 2
235000019333 sodium laurylsulphate Nutrition 0.000 claims description 2
239000013583 drug formulation Substances 0.000 claims 15
208000012886 Vertigo Diseases 0.000 claims 1
230000003288 anthiarrhythmic effect Effects 0.000 claims 1
230000003257 anti-anginal effect Effects 0.000 claims 1
239000003416 antiarrhythmic agent Substances 0.000 claims 1
229940005530 anxiolytics Drugs 0.000 claims 1
229940088623 biologically active substance Drugs 0.000 claims 1
-1 vasodictators Substances 0.000 claims 1
231100000889 vertigo Toxicity 0.000 claims 1
230000001362 anti-vertigo Effects 0.000 abstract description 2
229940124549 vasodilator Drugs 0.000 abstract description 2
239000003071 vasodilator agent Substances 0.000 abstract description 2
206010002383 Angina Pectoris Diseases 0.000 abstract 1
229940123907 Disease modifying antirheumatic drug Drugs 0.000 abstract 1
230000000202 analgesic effect Effects 0.000 abstract 1
230000000049 anti-anxiety effect Effects 0.000 abstract 1
230000001430 anti-depressive effect Effects 0.000 abstract 1
230000003276 anti-hypertensive effect Effects 0.000 abstract 1
230000002522 swelling effect Effects 0.000 abstract 1
239000003826 tablet Substances 0.000 description 71
238000002474 experimental method Methods 0.000 description 39
238000012360 testing method Methods 0.000 description 19
238000000338 in vitro Methods 0.000 description 18
239000000725 suspension Substances 0.000 description 10
238000011282 treatment Methods 0.000 description 10
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
239000000126 substance Substances 0.000 description 7
230000003628 erosive effect Effects 0.000 description 6
230000000975 bioactive effect Effects 0.000 description 5
VYVKHNNGDFVQGA-UHFFFAOYSA-N 3,4-dimethoxybenzoic acid 4-[ethyl-[1-(4-methoxyphenyl)propan-2-yl]amino]butyl ester Chemical compound C=1C=C(OC)C=CC=1CC(C)N(CC)CCCCOC(=O)C1=CC=C(OC)C(OC)=C1 VYVKHNNGDFVQGA-UHFFFAOYSA-N 0.000 description 4
229920002785 Croscarmellose sodium Polymers 0.000 description 4
229920002678 cellulose Polymers 0.000 description 4
239000001913 cellulose Substances 0.000 description 4
235000010980 cellulose Nutrition 0.000 description 4
229960003529 diazepam Drugs 0.000 description 4
AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 4
229960003577 mebeverine Drugs 0.000 description 4
230000007246 mechanism Effects 0.000 description 4
XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 4
229960004618 prednisone Drugs 0.000 description 4
230000008961 swelling Effects 0.000 description 4
NYSDRDDQELAVKP-SFHVURJKSA-N flesinoxan Chemical group C([C@@H](O1)CO)OC2=C1C=CC=C2N(CC1)CCN1CCNC(=O)C1=CC=C(F)C=C1 NYSDRDDQELAVKP-SFHVURJKSA-N 0.000 description 3
229950003678 flesinoxan Drugs 0.000 description 3
239000010410 layer Substances 0.000 description 3
238000013268 sustained release Methods 0.000 description 3
239000012730 sustained-release form Substances 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
210000002700 urine Anatomy 0.000 description 3
229940124599 anti-inflammatory drug Drugs 0.000 description 2
238000005336 cracking Methods 0.000 description 2
238000009792 diffusion process Methods 0.000 description 2
238000004090 dissolution Methods 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
230000000694 effects Effects 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
239000012528 membrane Substances 0.000 description 2
230000035699 permeability Effects 0.000 description 2
238000011160 research Methods 0.000 description 2
238000012216 screening Methods 0.000 description 2
230000036325 urinary excretion Effects 0.000 description 2
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
206010009900 Colitis ulcerative Diseases 0.000 description 1
208000011231 Crohn disease Diseases 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
235000019739 Dicalciumphosphate Nutrition 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
229920000881 Modified starch Polymers 0.000 description 1
108010019160 Pancreatin Proteins 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
201000006704 Ulcerative Colitis Diseases 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
230000009471 action Effects 0.000 description 1
229960004538 alprazolam Drugs 0.000 description 1
VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
239000004004 anti-anginal agent Substances 0.000 description 1
229940124347 antiarthritic drug Drugs 0.000 description 1
238000013459 approach Methods 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
UUQMNUMQCIQDMZ-UHFFFAOYSA-N betahistine Chemical compound CNCCC1=CC=CC=N1 UUQMNUMQCIQDMZ-UHFFFAOYSA-N 0.000 description 1
229960004536 betahistine Drugs 0.000 description 1
229940124630 bronchodilator Drugs 0.000 description 1
239000000168 bronchodilator agent Substances 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
239000011247 coating layer Substances 0.000 description 1
239000007891 compressed tablet Substances 0.000 description 1
239000000470 constituent Substances 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
230000001186 cumulative effect Effects 0.000 description 1
NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
229940038472 dicalcium phosphate Drugs 0.000 description 1
229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
238000003255 drug test Methods 0.000 description 1
229940088598 enzyme Drugs 0.000 description 1
239000000945 filler Substances 0.000 description 1
229960004038 fluvoxamine Drugs 0.000 description 1
CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 description 1
230000037406 food intake Effects 0.000 description 1
235000011389 fruit/vegetable juice Nutrition 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
238000002649 immunization Methods 0.000 description 1
230000003053 immunization Effects 0.000 description 1
230000006872 improvement Effects 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
208000002551 irritable bowel syndrome Diseases 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
235000019426 modified starch Nutrition 0.000 description 1
229940055695 pancreatin Drugs 0.000 description 1
230000035515 penetration Effects 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
239000008028 pharmaceutical plasticizer Substances 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
229920000193 polymethacrylate Polymers 0.000 description 1
238000003825 pressing Methods 0.000 description 1
230000008569 process Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
230000000541 pulsatile effect Effects 0.000 description 1
125000001453 quaternary ammonium group Chemical group 0.000 description 1
238000000926 separation method Methods 0.000 description 1
239000000243 solution Substances 0.000 description 1
239000007921 spray Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
239000007916 tablet composition Substances 0.000 description 1
229960000814 tetanus toxoid Drugs 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
238000005303 weighing Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/282—Organic compounds, e.g. fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Virology (AREA)
Pulmonology (AREA)
Mycology (AREA)
Microbiology (AREA)
Immunology (AREA)
Cardiology (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Pain & Pain Management (AREA)
Neurosurgery (AREA)
Heart & Thoracic Surgery (AREA)
Rheumatology (AREA)
Anesthesiology (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Cosmetics (AREA)

HR96202651,4A 1996-09-23 1997-09-16 Oral delayed immediate release medical formulation and method for preparing the same HRP970493A2 (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP96202651		1996-09-23

Publications (1)

Publication Number	Publication Date
HRP970493A2 true HRP970493A2 (en)	1998-08-31

Family

ID=8224414

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HR96202651,4A HRP970493A2 (en)	1996-09-23	1997-09-16	Oral delayed immediate release medical formulation and method for preparing the same

Country Status (29)

Country	Link
US (1)	US6183780B1 (es)
EP (1)	EP0939623B1 (es)
JP (1)	JP4947824B2 (es)
KR (1)	KR100501966B1 (es)
CN (1)	CN1161110C (es)
AT (1)	ATE213627T1 (es)
AU (1)	AU717711B2 (es)
BR (1)	BR9711303A (es)
CA (1)	CA2263921C (es)
CZ (1)	CZ294641B6 (es)
DE (1)	DE69710756T2 (es)
DK (1)	DK0939623T3 (es)
DZ (1)	DZ2314A1 (es)
ES (1)	ES2172003T3 (es)
HR (1)	HRP970493A2 (es)
HU (1)	HU226693B1 (es)
ID (1)	ID22039A (es)
IL (1)	IL128565A (es)
JO (1)	JO2066B1 (es)
NO (1)	NO325763B1 (es)
NZ (1)	NZ334463A (es)
PL (1)	PL189016B1 (es)
PT (1)	PT939623E (es)
RU (1)	RU2193395C2 (es)
SK (1)	SK284263B6 (es)
TR (1)	TR199900641T2 (es)
UA (1)	UA72182C2 (es)
WO (1)	WO1998013029A1 (es)
ZA (1)	ZA978431B (es)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20030109503A1 (en) *	1995-06-06	2003-06-12	Smithkline Beecham P.L.C.	Pharmaceutical formulations comprising clavulanic acid alone or in combination with other beta-lactam antibiotics
SK17422000A3 (sk) *	1998-05-20	2001-09-11	The Liposome Company, Inc.	Kompozöcie ¬astöc
SE9802973D0 (sv) *	1998-09-03	1998-09-03	Astra Ab	Immediate release tablet
US20010055613A1 (en) *	1998-10-21	2001-12-27	Beth A. Burnside	Oral pulsed dose drug delivery system
MXPA01004381A (es) *	1998-11-02	2005-09-08	Elan Corp Plc	Composicion de multiparticulado de liberacion modificada.
US6294199B1 (en)	1999-04-13	2001-09-25	Beecham Pharmaceuticals (Pte) Limited	Method of treating a bacterial infection comprising administering amoxycillin
US6878386B1 (en)	1999-04-13	2005-04-12	Beecham Pharmaceuticals (Pte) Limited	Method of treating a bacterial infection comprising amoxycillin and potassium clavulanate
US7250176B1 (en)	1999-04-13	2007-07-31	Beecham Pharmaceuticals (Pte) Limited	Method of treating a bacterial infection
IE990406A1 (en) *	1999-05-20	2000-12-27	Elan Corp Plc	Multiparticulate controlled release selective serotonin reuptake inhibitor formulations.
EP1064937A1 (en) *	1999-06-28	2001-01-03	Sanofi-Synthelabo	Timed dual release dosage forms comprising a short acting hypnotic or a salt thereof
EP1074249A1 (en) *	1999-07-27	2001-02-07	Jagotec Ag	A pharmaceutical tablet system for releasing at least one active substance during a release period subsequent to a no-release period
US6592869B2 (en)	1999-08-24	2003-07-15	Teva Pharmaceutical Industries, Ltd.	Vaccine composition and method of using the same
IL148247A0 (en)	1999-08-24	2002-09-12	Teva Pharma	A vaccine composition and method of using the same
US6485746B1 (en)	2000-08-25	2002-11-26	Neurocrine Biosciences, Inc.	Controlled-release sedative-hypnotic compositions and methods related thereto
ATE241968T1 (de) *	1999-08-26	2003-06-15	Neurocrine Biosciences Inc	Sedativ hypnotische zusammensetzungen mit gesteuerter freisetzung und diesbezügliche verfahren
DE10012555A1 (de) *	2000-03-15	2001-09-20	Merck Patent Gmbh	Glucocorticoide in einer Modified Release-Formulierung
US6720005B1 (en) *	2000-07-07	2004-04-13	The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University	Coated, platform-generating tablet
US6756057B2 (en)	2000-10-12	2004-06-29	Beecham Pharmaceuticals (Pte) Limited	Amoxicillin and potassium clavulanate dosage form
WO2002030392A2 (en)	2000-10-12	2002-04-18	Beecham Pharmaceuticals (Pte) Limited	Formulation containing amoxicillin
US6913768B2 (en) *	2002-09-24	2005-07-05	Shire Laboratories, Inc.	Sustained release delivery of amphetamine salts
US20080220074A1 (en) *	2002-10-04	2008-09-11	Elan Corporation Plc	Gamma radiation sterilized nanoparticulate docetaxel compositions and methods of making same
US7772188B2 (en)	2003-01-28	2010-08-10	Ironwood Pharmaceuticals, Inc.	Methods and compositions for the treatment of gastrointestinal disorders
KR101192722B1 (ko) *	2003-04-24	2012-10-18	자고텍 아게	정해진 핵 위치를 가지는 서방성 정제
US20070148229A1 (en) *	2003-04-24	2007-06-28	Jagotec Ag	Tablet with coloured core
WO2005016318A1 (en) *	2003-08-08	2005-02-24	Biovail Laboratories Inc.	Modified-release tablet of bupropion hydrochloride
CA2544678C (en)	2003-11-05	2013-12-31	Sunesis Pharmaceuticals, Inc.	Modulators of cellular adhesion
DE602005025755D1 (de)	2004-06-04	2011-02-17	Teva Pharma	Irbesartan enthaltende pharmazeutische zusammensetzung
DE102004043863A1 (de)	2004-09-10	2006-03-16	Nitec Pharma Ag	Tabletten mit orts- und zeitgesteuerter Wirkstofffreisetzung im Gastrointestinum
GB0423964D0 (en) *	2004-10-28	2004-12-01	Jagotec Ag	Dosage form
WO2006063078A2 (en) *	2004-12-08	2006-06-15	Elan Corporation, Plc	Topiramate pharmaceuticals composition
AU2006235483B2 (en) *	2005-04-12	2010-11-25	Elan Pharma International Limited	Controlled release compositions comprising a cephalosporin for the treatment of a bacterial infection
DK2444079T3 (en)	2005-05-17	2017-01-30	Sarcode Bioscience Inc	Compositions and Methods for the Treatment of Eye Diseases
WO2007037790A2 (en) *	2005-06-08	2007-04-05	Elan Corporation, Plc	Modified release famciclovir compositions
CA2617051C (en)	2005-07-29	2013-12-17	Stichting Groningen Centre For Drug Research	Ph-controlled pulsatile delivery system, methods for preparation and use thereof
US20070036859A1 (en) *	2005-08-11	2007-02-15	Perry Ronald L	Sustained release antihistamine and decongestant composition
TWI274889B (en) *	2005-10-06	2007-03-01	Elan Microelectronics Corp	Resistive touch screen measurement system
US8187633B2 (en) *	2005-11-03	2012-05-29	Sun Pharma Advanced Research Company Limited	Controlled release coated tablets having prolonged gastric retention
RU2308941C1 (ru) *	2006-05-10	2007-10-27	Открытое акционерное общество "Московское производственное химико-фармацевтическое объединение им. Н.А. Семашко"	Твердая лекарственная форма, обладающая гистаминоподобным действием, и способ ее получения
SI2049123T1 (sl) *	2006-08-03	2013-04-30	Horizon Pharma Ag	Zdravljenje revmatoznih bolezni z zadrĹľanim sproĹˇÄŤanjem glukokortikoida
US20080081067A1 (en) *	2006-10-03	2008-04-03	Gupta Manishkumar	Sustained release pharmaceutical compositions of venlafaxine and process for preparation thereof
RU2356539C2 (ru) *	2006-12-28	2009-05-27	Закрытое Акционерное Общество "Канонфарма Продакшн"	Твердая лекарственная форма бетагистина дигидрохлорида и способ ее получения
US8969514B2 (en)	2007-06-04	2015-03-03	Synergy Pharmaceuticals, Inc.	Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
MX354786B (es)	2007-06-04	2018-03-21	Synergy Pharmaceuticals Inc	Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
WO2009021127A2 (en) *	2007-08-07	2009-02-12	Neurogen Corporation	Controlled released compositions
ES2830024T3 (es)	2007-10-19	2021-06-02	Novartis Ag	Composiciones y métodos para el tratamiento del edema macular
WO2009139817A2 (en)	2008-04-15	2009-11-19	Sarcode Corporation	Crystalline pharmaceutical and methods of preparation and use thereof
ES2522968T3 (es)	2008-06-04	2014-11-19	Synergy Pharmaceuticals Inc.	Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
AU2009270833B2 (en)	2008-07-16	2015-02-19	Bausch Health Ireland Limited	Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
TWI494108B (zh) *	2009-01-26	2015-08-01	Nitec Pharma Ag	糖皮質激素用以製備嚴重夜間氣喘用之於延遲釋放型的藥物之用途
NZ582836A (en) *	2009-01-30	2011-06-30	Nitec Pharma Ag	Delayed-release glucocorticoid treatment of rheumatoid arthritis by improving signs and symptoms, showing major or complete clinical response and by preventing from joint damage
WO2011050175A1 (en)	2009-10-21	2011-04-28	Sarcode Corporation	Crystalline pharmaceutical and methods of preparation and use thereof
EP2314296A1 (en) *	2009-10-22	2011-04-27	Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi	Orally Disintegrating Tablets of Betahistine
US9616097B2 (en)	2010-09-15	2017-04-11	Synergy Pharmaceuticals, Inc.	Formulations of guanylate cyclase C agonists and methods of use
WO2012071220A1 (en) *	2010-11-23	2012-05-31	Transcept Pharmaceuticals, Inc.	Compositions and methods for once-daily administration of a trilayer osmotic tablet
RU2453308C1 (ru) *	2010-12-20	2012-06-20	Государственное образовательное учреждение высшего профессионального образования "БАШКИРСКИЙ ГОСУДАРСТВЕННЫЙ МЕДИЦИНСКИЙ УНИВЕРСИТЕТ ФЕДЕРАЛЬНОГО АГЕНТСТВА ПО ЗДРАВООХРАНЕНИЮ И СОЦИАЛЬНОМУ РАЗВИТИЮ"	Драже с оксиметилурацилом и мебеверина гидрохлоридом для лечения функциональных заболеваний желудочно-кишечного тракта
KR102258769B1 (ko) *	2011-10-14	2021-06-01	지엘팜텍주식회사	장용소화효소제 및 그 제조방법
DE102012105528A1 (de)	2012-06-25	2014-01-02	Hennig Arzneimittel Gmbh & Co. Kg	Arzneiform zur Freisetzung von Wirkstoffen
KR20200108932A (ko)	2012-07-25	2020-09-21	에스에이알코드 바이오사이언스 인코포레이티드	Lfa-1 저해제 및 그의 다형체
WO2014131024A2 (en)	2013-02-25	2014-08-28	Synergy Pharmaceuticals Inc.	Agonists of guanylate cyclase and their uses
AU2014235209B2 (en)	2013-03-15	2018-06-14	Bausch Health Ireland Limited	Guanylate cyclase receptor agonists combined with other drugs
AU2014235215A1 (en)	2013-03-15	2015-10-01	Synergy Pharmaceuticals Inc.	Agonists of guanylate cyclase and their uses
JP6661531B2 (ja)	2013-10-10	2020-03-11	シナジーファーマシューティカルズインコーポレイテッド	オピオイド誘発性機能障害の治療に有用なグアニル酸シクラーゼのアゴニスト
HK1245079A1 (zh) *	2015-06-30	2018-08-24	纽拉德有限公司	新颖呼吸控制调节化合物以及其制备和使用方法
US10653744B2 (en)	2016-01-11	2020-05-19	Bausch Health Ireland Limited	Formulations and methods for treating ulcerative colitis
CN108836948B (zh) *	2018-06-11	2024-04-12	宁波西敦医药包衣科技有限公司	一种利用包衣技术实现营养素可控制释放的产品
RU2695135C1 (ru) *	2018-07-11	2019-07-22	Федеральное государственное унитарное предприятие "Научно-исследовательский институт гигиены, профпатологии и экологии человека" Федерального медико-биологического агентства	Двухуровневая микрогранулированная форма терапевтического пептида для перорального применения и способ ее получения
CN110403912A (zh) *	2019-09-04	2019-11-05	西安科力康医药科技有限公司	缓控释包衣粉

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CH666405A5 (de) *	1985-06-24	1988-07-29	Ciba Geigy Ag	Feste, haltbare darreichungsformen mit elastischem filmueberzug.
GB8524001D0 (en) *	1985-09-30	1985-11-06	Glaxo Group Ltd	Pharmaceutical composition
US5122384A (en) *	1989-05-05	1992-06-16	Kv Pharmaceutical Company	Oral once-per-day organic nitrate formulation which does not induce tolerance
US5133974A (en) *	1989-05-05	1992-07-28	Kv Pharmaceutical Company	Extended release pharmaceutical formulations
US5032405A (en) *	1989-09-27	1991-07-16	Warner-Lambert Company	Oral pharmaceutical composition for acid sensitive proteinaceous agents
FR2655266B1 (fr) *	1989-12-05	1992-04-03	Smith Kline French Lab	Compositions pharmaceutiques a base de cimetidine.
US5229131A (en) *	1990-02-05	1993-07-20	University Of Michigan	Pulsatile drug delivery system
US5158777A (en) *	1990-02-16	1992-10-27	E. R. Squibb & Sons, Inc.	Captopril formulation providing increased duration of activity
GB9104854D0 (en) *	1991-03-07	1991-04-17	Reckitt & Colmann Prod Ltd	Sustained release compositions
US5286497A (en)	1991-05-20	1994-02-15	Carderm Capital L.P.	Diltiazem formulation
HU227530B1 (en) *	1991-11-22	2011-07-28	Warner Chilcott Company	Delayed-release compositions containing risedronate and process for their production
AU3949093A (en) *	1992-03-31	1993-11-08	Benzon Pharma A/S	A pharmaceutical formulation
US5500227A (en) *	1993-11-23	1996-03-19	Euro-Celtique, S.A.	Immediate release tablet cores of insoluble drugs having sustained-release coating
HUT77530A (hu) *	1994-05-06	1998-05-28	Pfizer Inc.	Azitromicint tartalmazó, szabályozott hatóanyag-felszabadítású dózisformák

1997
- 1997-09-16 HR HR96202651,4A patent/HRP970493A2/hr not_active Application Discontinuation
- 1997-09-18 KR KR10-1999-7002380A patent/KR100501966B1/ko not_active Expired - Fee Related
- 1997-09-18 DE DE69710756T patent/DE69710756T2/de not_active Expired - Lifetime
- 1997-09-18 NZ NZ334463A patent/NZ334463A/xx not_active IP Right Cessation
- 1997-09-18 CZ CZ1999995A patent/CZ294641B6/cs not_active IP Right Cessation
- 1997-09-18 TR TR1999/00641T patent/TR199900641T2/xx unknown
- 1997-09-18 IL IL12856597A patent/IL128565A/xx not_active IP Right Cessation
- 1997-09-18 JP JP51526398A patent/JP4947824B2/ja not_active Expired - Fee Related
- 1997-09-18 DK DK97943895T patent/DK0939623T3/da active
- 1997-09-18 PT PT97943895T patent/PT939623E/pt unknown
- 1997-09-18 BR BR9711303A patent/BR9711303A/pt not_active Application Discontinuation
- 1997-09-18 RU RU99108461/14A patent/RU2193395C2/ru not_active IP Right Cessation
- 1997-09-18 ID IDW990114A patent/ID22039A/id unknown
- 1997-09-18 ZA ZA9708431A patent/ZA978431B/xx unknown
- 1997-09-18 AT AT97943895T patent/ATE213627T1/de active
- 1997-09-18 UA UA99042314A patent/UA72182C2/uk unknown
- 1997-09-18 AU AU45570/97A patent/AU717711B2/en not_active Ceased
- 1997-09-18 CA CA002263921A patent/CA2263921C/en not_active Expired - Fee Related
- 1997-09-18 HU HU9904121A patent/HU226693B1/hu not_active IP Right Cessation
- 1997-09-18 SK SK376-99A patent/SK284263B6/sk not_active IP Right Cessation
- 1997-09-18 WO PCT/EP1997/005234 patent/WO1998013029A1/en not_active Ceased
- 1997-09-18 ES ES97943895T patent/ES2172003T3/es not_active Expired - Lifetime
- 1997-09-18 CN CNB971981671A patent/CN1161110C/zh not_active Expired - Fee Related
- 1997-09-18 PL PL97332245A patent/PL189016B1/pl not_active IP Right Cessation
- 1997-09-18 EP EP97943895A patent/EP0939623B1/en not_active Expired - Lifetime
- 1997-09-19 US US08/934,196 patent/US6183780B1/en not_active Expired - Lifetime
- 1997-09-21 JO JO19972066A patent/JO2066B1/en active
- 1997-09-22 DZ DZ970164A patent/DZ2314A1/xx active
1999
- 1999-03-22 NO NO19991385A patent/NO325763B1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
CZ99599A3 (cs)	1999-06-16
HUP9904121A2 (hu)	2000-04-28
CZ294641B6 (cs)	2005-02-16
US6183780B1 (en)	2001-02-06
BR9711303A (pt)	1999-08-17
DE69710756D1 (de)	2002-04-04
SK284263B6 (sk)	2004-12-01
PL332245A1 (en)	1999-08-30
HU226693B1 (en)	2009-06-29
DZ2314A1 (fr)	2002-12-28
AU4557097A (en)	1998-04-17
CA2263921C (en)	2006-05-23
AU717711B2 (en)	2000-03-30
PT939623E (pt)	2002-08-30
NZ334463A (en)	2000-12-22
PL189016B1 (pl)	2005-06-30
DK0939623T3 (da)	2002-06-10
IL128565A (en)	2003-02-12
ZA978431B (en)	1998-03-26
CN1161110C (zh)	2004-08-11
CN1231601A (zh)	1999-10-13
ES2172003T3 (es)	2002-09-16
ID22039A (id)	1999-08-26
NO325763B1 (no)	2008-07-14
SK37699A3 (en)	1999-08-06
NO991385L (no)	1999-05-25
UA72182C2 (en)	2005-02-15
JO2066B1 (en)	2000-05-21
JP4947824B2 (ja)	2012-06-06
JP2001500885A (ja)	2001-01-23
EP0939623A1 (en)	1999-09-08
KR20010029536A (ko)	2001-04-06
KR100501966B1 (ko)	2005-07-20
IL128565A0 (en)	2000-01-31
WO1998013029A1 (en)	1998-04-02
CA2263921A1 (en)	1998-04-02
RU2193395C2 (ru)	2002-11-27
DE69710756T2 (de)	2002-10-24
EP0939623B1 (en)	2002-02-27
TR199900641T2 (xx)	1999-07-21
ATE213627T1 (de)	2002-03-15
HK1019852A1 (en)	2000-03-03
HUP9904121A3 (en)	2004-10-28
NO991385D0 (no)	1999-03-22

Legal Events

Date	Code	Title	Description
1998-08-31	A1OB	Publication of a patent application
1999-10-28	ODBC	Application rejected

Publication	Publication Date	Title
HRP970493A2 (en)	1998-08-31	Oral delayed immediate release medical formulation and method for preparing the same
CA1148084A (en)	1983-06-14	Dipyridamol sustained release forms and processes for the preparation thereof
AU671830B2 (en)	1996-09-12	A Pharmaceutical Preparation of Dichloromethylene Bisphosphonic Acid with Enteric Coating for Oral Use
CA2290017C (en)	2004-06-29	Method for producing orally administered, solid pharmaceutical products with controlled release of the active substance
EP0572486B1 (en)	1995-11-08	Delayed release oral dosage forms for treatment of intestinal disorders
US5482718A (en)	1996-01-09	Colon-targeted delivery system
EP0255404A1 (en)	1988-02-03	Sustained release ibuprofen formulation
AU783911B2 (en)	2005-12-22	Coated solid dosage forms
JP2006096771A (ja)	2006-04-13	制御放出モルヒネ製剤
WO1998026767A2 (en)	1998-06-25	Site-specific controlled release dosage formulation for mesalamine
JPH0372417A (ja)	1991-03-27	腸内適所放出経口製剤
CA2579732C (en)	2014-08-12	Tablets with site time-controlled gastrointestinal release of active ingredient
CN102335431A (zh)	2012-02-01	一种给药组合物及其制备和使用方法
HK1019852B (en)	2002-06-07	Oral delayed immediate release formulation and method of preparation therefor
AU2011232809B2 (en)	2014-03-20	Tablets with site and time-controlled gastrointestinal release of active ingredient
CN107158095A (zh)	2017-09-15	一种三黄肠溶给药组合物及其制备方法
MXPA99000903A (es)	1999-06-01	Formulaciones de unidades multiples de tramadol